Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 23:00 local time 6th of December 2020

Situation Report No. 192 - State of Kuwait 7th of December, 2020




	Glo	bal	Eastern Mediterranean Region		
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths	
Total	65,870,030	1,523,583	4,288,324	107,247	
New	605,211	10,264	31,277	619	

State of Kuwait

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	144,369	140,035	891	3,443	81	1,141,794
New	205	425	2	-	-	4,102

HIGHLIGHTS

- Recovery rate reaches 97% and case fatality rate reaches 0.62%.
- WHO provides updated guidance on COVID-19 therapeutics, see link.
- WHO produces guide on developing a national deployment and vaccination Planning for COVID-19 vaccines, see link.
- WHO updated guidance on mask use in the context of COVID-19, see link.



IMPORTANT LINKS

- MoH update of COVID-19: https://corona.e.gov.kw/en/
- WHO's COVID-19 weekly situation reports:

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

- WHO's COVID-19 dashboard: https://covid19.who.int/
- WHO's Therapeutics and COVID-19: living guideline:


https://www.who.int/publications/i/item/the rapeutics-and-covid-19-living-guideline

WHO guide on developing a national deployment and vaccination Plan:

https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccine_deployment-2020.1

• WHO updated guidance on mask use in the context of COVID-19:

https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak



IMPORTANT DEFINITIONS

How will we know if a COVID-19 vaccine is safe?

There are many strict protections in place to help ensure that COVID-19 vaccines will be safe. Like all vaccines, COVID-19 vaccines should go through a rigorous, multi-stage testing process, including large (phase III) trials that involve tens of thousands of people. These trials are specifically designed to identify any common side effects or other safety concerns.

If clinical trials shows that a vaccine is safe and effective, a series of independent reviews of the efficacy and safety evidence is required, including regulatory review and approval in the country where the vaccine is manufactured, before WHO considers a vaccine product for prequalification. Part of this process also involves a review of all the safety evidence by the Global Advisory Committee in Vaccine Safety. An external panel of experts convened by WHO will analyse the results from clinical trials. After a COVID-19 vaccine is introduced, WHO will support monitoring for any safety concerns on an ongoing basis.



• The National Focal Person is Dr Buthaina AlMudhaf, Assistant Undersecretary, Ministry of Health, email: AlMudhaf@gmail.com

